Cargando…

Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence

(1) Background: healthcare-associated infections are one of the most frequent adverse events in healthcare delivery worldwide. Several antibiotic resistance mechanisms have been developed, including those to carbapenemase. Cefiderocol (CFD) is a novel siderophore cephalosporin designed to treat carb...

Descripción completa

Detalles Bibliográficos
Autores principales: Sansone, Pasquale, Giaccari, Luca Gregorio, Coppolino, Francesco, Aurilio, Caterina, Barbarisi, Alfonso, Passavanti, Maria Beatrice, Pota, Vincenzo, Pace, Maria Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311995/
https://www.ncbi.nlm.nih.gov/pubmed/35884158
http://dx.doi.org/10.3390/antibiotics11070904
_version_ 1784753731240198144
author Sansone, Pasquale
Giaccari, Luca Gregorio
Coppolino, Francesco
Aurilio, Caterina
Barbarisi, Alfonso
Passavanti, Maria Beatrice
Pota, Vincenzo
Pace, Maria Caterina
author_facet Sansone, Pasquale
Giaccari, Luca Gregorio
Coppolino, Francesco
Aurilio, Caterina
Barbarisi, Alfonso
Passavanti, Maria Beatrice
Pota, Vincenzo
Pace, Maria Caterina
author_sort Sansone, Pasquale
collection PubMed
description (1) Background: healthcare-associated infections are one of the most frequent adverse events in healthcare delivery worldwide. Several antibiotic resistance mechanisms have been developed, including those to carbapenemase. Cefiderocol (CFD) is a novel siderophore cephalosporin designed to treat carbapenem-resistant bacteria. (2) Methods: we performed a systematic review of all cases reported in the literature to outline the existing evidence. We evaluated real-world evidence studies of CFD in the treatment of carbapenem-resistant (CR) bacteria. (3) Results: a total of 19 publications treating cases of infection by CR bacteria were included. The three most frequent CR pathogens were Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. A regimen of 2 g every 8 h was most frequently adopted for CFD with a mean treatment duration of 25.6 days. CFD was generally well tolerated, with fewer side effects. The success rate of CFD therapy was satisfactory and almost 70% of patients showed clinical recovery; of these, nearly half showed negative blood cultures and infection-free status. (4) Conclusions: This review indicates that CFD is active against important GN organisms including Enterobacteriaceae, P. aeruginosa, and A. baumannii. CFD seems to have a safe profile.
format Online
Article
Text
id pubmed-9311995
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93119952022-07-26 Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence Sansone, Pasquale Giaccari, Luca Gregorio Coppolino, Francesco Aurilio, Caterina Barbarisi, Alfonso Passavanti, Maria Beatrice Pota, Vincenzo Pace, Maria Caterina Antibiotics (Basel) Review (1) Background: healthcare-associated infections are one of the most frequent adverse events in healthcare delivery worldwide. Several antibiotic resistance mechanisms have been developed, including those to carbapenemase. Cefiderocol (CFD) is a novel siderophore cephalosporin designed to treat carbapenem-resistant bacteria. (2) Methods: we performed a systematic review of all cases reported in the literature to outline the existing evidence. We evaluated real-world evidence studies of CFD in the treatment of carbapenem-resistant (CR) bacteria. (3) Results: a total of 19 publications treating cases of infection by CR bacteria were included. The three most frequent CR pathogens were Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. A regimen of 2 g every 8 h was most frequently adopted for CFD with a mean treatment duration of 25.6 days. CFD was generally well tolerated, with fewer side effects. The success rate of CFD therapy was satisfactory and almost 70% of patients showed clinical recovery; of these, nearly half showed negative blood cultures and infection-free status. (4) Conclusions: This review indicates that CFD is active against important GN organisms including Enterobacteriaceae, P. aeruginosa, and A. baumannii. CFD seems to have a safe profile. MDPI 2022-07-06 /pmc/articles/PMC9311995/ /pubmed/35884158 http://dx.doi.org/10.3390/antibiotics11070904 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sansone, Pasquale
Giaccari, Luca Gregorio
Coppolino, Francesco
Aurilio, Caterina
Barbarisi, Alfonso
Passavanti, Maria Beatrice
Pota, Vincenzo
Pace, Maria Caterina
Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
title Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
title_full Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
title_fullStr Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
title_full_unstemmed Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
title_short Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
title_sort cefiderocol for carbapenem-resistant bacteria: handle with care! a review of the real-world evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311995/
https://www.ncbi.nlm.nih.gov/pubmed/35884158
http://dx.doi.org/10.3390/antibiotics11070904
work_keys_str_mv AT sansonepasquale cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence
AT giaccarilucagregorio cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence
AT coppolinofrancesco cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence
AT auriliocaterina cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence
AT barbarisialfonso cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence
AT passavantimariabeatrice cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence
AT potavincenzo cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence
AT pacemariacaterina cefiderocolforcarbapenemresistantbacteriahandlewithcareareviewoftherealworldevidence